COMPOSÉ SE LIANT AU PPARG MAIS N'AGISSANT PAS COMME PROMOTEUR ET COMPOSITION PHARMACEUTIQUE POUR LE TRAITEMENT DE MALADIES ASSOCIÉES AU PPARG CONTENANT CELUI-CI UTILISÉ COMME PRINCIPE ACTIF
The present invention relates to a compound inhibiting CDK5-mediated PPARG phosphorylation and a pharmaceutical composition for treating PPARG-related diseases containing the same as an active ingredient. A compound represented by formula 1 or an optical isomer thereof according to the present invention binds to PPARG at a high affinity level, but does not act as an agonist, thereby inducing no gene transcription； blocks CDK5, which is a cause of PPARG phosphorylation, thereby causing no side effects of existing anti-diabetics； can be formulated into drugs due to improved pharmacological properties thereof； and can be favorably used as a pharmaceutical composition for treating PPARG-related diseases due to an excellent treatment effect on PPARG-related diseases.
